Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview

Atara Biotherapeutics

07/08/2026 12:55

Atara Biotherapeutics, Inc. ATRA.OQ ATRA.O is expected to  show a fall in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Thousand Oaks California-based  company is expected to report a 97.9% decrease in revenue to $366.67 thousand from $17.58 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Atara Biotherapeutics, Inc. is for a loss of 31 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Atara Biotherapeutics, Inc. is $13.00, about 57.6% above its last closing price of $8.25
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.41
-0.40
-0.29
Beat
28.4
Dec. 31 2026
-0.14
-0.17
-0.25
Missed
-45.9
Sep. 30 2025
-0.82
-0.86
-0.32
Beat
62.8​
Jun. 30 2025
-0.32
-0.46
0.19
Beat
141.3
​​Mar. 31 2025
-1.96
-1.98
3.50
Beat
276.8
Dec. 31 2024
-3.76
-3.58
-1.19
Beat
66.7​
Sep. 30 2024
-2.11
-1.93
-2.93
Missed
-51.6
Jun. 30 2024
-1.38
-1.56
-3.10
Missed
-98.4
This summary was machine generated August 7 at 11:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)